Kapvay

Hot Flashes, Smoke, clonidine suppression test + 15 more

Treatment

20 Active Studies for Kapvay

What is Kapvay

Clonidine

The Generic name of this drug

Treatment Summary

Clonidine is a medication used to treat high blood pressure, severe pain, and Attention Deficit Hyperactivity Disorder (ADHD). It works by activating alpha-2 adrenoceptors in the body. Clonidine was approved by the FDA in 1974 and has been commonly prescribed ever since.

Catapres

is the brand name

image of different drug pills on a surface

Kapvay Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Catapres

Clonidine

1974

447

Effectiveness

How Kapvay Affects Patients

Clonidine works by activating certain receptors in the body, which can reduce blood pressure, make you sleepy, and decrease electrical activity in the nerves. The amount of clonidine needed for it to be effective varies from person to person, and it is typically taken twice a day. The usual recommended dose is between 0.1mg to 2.4mg daily.

How Kapvay works in the body

Clonidine works by binding to the Alpha-2 adrenoceptor, a G-protein found in the brain. This binding causes a change in the G-protein's structure, allowing it to interact with an effector. This process can cause decreased blood pressure, inhibited pain signals, and increased sleepiness. It can also affect regulators of blood pressure in certain areas of the brain.

When to interrupt dosage

The advised measure of Kapvay is contingent upon the diagnosed condition, including methadone, diabetic diarrhea and Hypertensive disease. The dosage fluctuates as per the administration technique (e.g. Oral or Tablet) provided in the table below.

Condition

Dosage

Administration

Hypertensive disease

, 0.1 mg, 0.2 mg, 0.3 mg, 0.5 mg/mL, 0.1 mg/mL, 0.01 mg/hour, 0.02 mg/hour, 0.03 mg/hour, 0.09 mg/mL, 0.17 mg, 0.26 mg, 0.025 mg, 0.15 mg, 25.0 mg

, Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Transdermal, Patch - Transdermal, Patch, Patch, extended release, Patch, extended release - Transdermal, For suspension, extended release - Oral, For suspension, extended release, Epidural, Injection, solution - Epidural, Kit, Kit - Oral, Suspension, extended release - Oral, Suspension, extended release

Pheochromocytoma

, 0.1 mg, 0.2 mg, 0.3 mg, 0.5 mg/mL, 0.1 mg/mL, 0.01 mg/hour, 0.02 mg/hour, 0.03 mg/hour, 0.09 mg/mL, 0.17 mg, 0.26 mg, 0.025 mg, 0.15 mg, 25.0 mg

, Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Transdermal, Patch - Transdermal, Patch, Patch, extended release, Patch, extended release - Transdermal, For suspension, extended release - Oral, For suspension, extended release, Epidural, Injection, solution - Epidural, Kit, Kit - Oral, Suspension, extended release - Oral, Suspension, extended release

Tourette Syndrome

, 0.1 mg, 0.2 mg, 0.3 mg, 0.5 mg/mL, 0.1 mg/mL, 0.01 mg/hour, 0.02 mg/hour, 0.03 mg/hour, 0.09 mg/mL, 0.17 mg, 0.26 mg, 0.025 mg, 0.15 mg, 25.0 mg

, Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Transdermal, Patch - Transdermal, Patch, Patch, extended release, Patch, extended release - Transdermal, For suspension, extended release - Oral, For suspension, extended release, Epidural, Injection, solution - Epidural, Kit, Kit - Oral, Suspension, extended release - Oral, Suspension, extended release

Disease

, 0.1 mg, 0.2 mg, 0.3 mg, 0.5 mg/mL, 0.1 mg/mL, 0.01 mg/hour, 0.02 mg/hour, 0.03 mg/hour, 0.09 mg/mL, 0.17 mg, 0.26 mg, 0.025 mg, 0.15 mg, 25.0 mg

, Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Transdermal, Patch - Transdermal, Patch, Patch, extended release, Patch, extended release - Transdermal, For suspension, extended release - Oral, For suspension, extended release, Epidural, Injection, solution - Epidural, Kit, Kit - Oral, Suspension, extended release - Oral, Suspension, extended release

Attention Deficit and Disruptive Behavior Disorders

, 0.1 mg, 0.2 mg, 0.3 mg, 0.5 mg/mL, 0.1 mg/mL, 0.01 mg/hour, 0.02 mg/hour, 0.03 mg/hour, 0.09 mg/mL, 0.17 mg, 0.26 mg, 0.025 mg, 0.15 mg, 25.0 mg

, Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Transdermal, Patch - Transdermal, Patch, Patch, extended release, Patch, extended release - Transdermal, For suspension, extended release - Oral, For suspension, extended release, Epidural, Injection, solution - Epidural, Kit, Kit - Oral, Suspension, extended release - Oral, Suspension, extended release

Smoke

, 0.1 mg, 0.2 mg, 0.3 mg, 0.5 mg/mL, 0.1 mg/mL, 0.01 mg/hour, 0.02 mg/hour, 0.03 mg/hour, 0.09 mg/mL, 0.17 mg, 0.26 mg, 0.025 mg, 0.15 mg, 25.0 mg

, Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Transdermal, Patch - Transdermal, Patch, Patch, extended release, Patch, extended release - Transdermal, For suspension, extended release - Oral, For suspension, extended release, Epidural, Injection, solution - Epidural, Kit, Kit - Oral, Suspension, extended release - Oral, Suspension, extended release

clonidine suppression test

, 0.1 mg, 0.2 mg, 0.3 mg, 0.5 mg/mL, 0.1 mg/mL, 0.01 mg/hour, 0.02 mg/hour, 0.03 mg/hour, 0.09 mg/mL, 0.17 mg, 0.26 mg, 0.025 mg, 0.15 mg, 25.0 mg

, Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Transdermal, Patch - Transdermal, Patch, Patch, extended release, Patch, extended release - Transdermal, For suspension, extended release - Oral, For suspension, extended release, Epidural, Injection, solution - Epidural, Kit, Kit - Oral, Suspension, extended release - Oral, Suspension, extended release

clozapine

, 0.1 mg, 0.2 mg, 0.3 mg, 0.5 mg/mL, 0.1 mg/mL, 0.01 mg/hour, 0.02 mg/hour, 0.03 mg/hour, 0.09 mg/mL, 0.17 mg, 0.26 mg, 0.025 mg, 0.15 mg, 25.0 mg

, Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Transdermal, Patch - Transdermal, Patch, Patch, extended release, Patch, extended release - Transdermal, For suspension, extended release - Oral, For suspension, extended release, Epidural, Injection, solution - Epidural, Kit, Kit - Oral, Suspension, extended release - Oral, Suspension, extended release

methadone

, 0.1 mg, 0.2 mg, 0.3 mg, 0.5 mg/mL, 0.1 mg/mL, 0.01 mg/hour, 0.02 mg/hour, 0.03 mg/hour, 0.09 mg/mL, 0.17 mg, 0.26 mg, 0.025 mg, 0.15 mg, 25.0 mg

, Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Transdermal, Patch - Transdermal, Patch, Patch, extended release, Patch, extended release - Transdermal, For suspension, extended release - Oral, For suspension, extended release, Epidural, Injection, solution - Epidural, Kit, Kit - Oral, Suspension, extended release - Oral, Suspension, extended release

Cancer Pain

, 0.1 mg, 0.2 mg, 0.3 mg, 0.5 mg/mL, 0.1 mg/mL, 0.01 mg/hour, 0.02 mg/hour, 0.03 mg/hour, 0.09 mg/mL, 0.17 mg, 0.26 mg, 0.025 mg, 0.15 mg, 25.0 mg

, Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Transdermal, Patch - Transdermal, Patch, Patch, extended release, Patch, extended release - Transdermal, For suspension, extended release - Oral, For suspension, extended release, Epidural, Injection, solution - Epidural, Kit, Kit - Oral, Suspension, extended release - Oral, Suspension, extended release

growth hormone stimulation test

, 0.1 mg, 0.2 mg, 0.3 mg, 0.5 mg/mL, 0.1 mg/mL, 0.01 mg/hour, 0.02 mg/hour, 0.03 mg/hour, 0.09 mg/mL, 0.17 mg, 0.26 mg, 0.025 mg, 0.15 mg, 25.0 mg

, Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Transdermal, Patch - Transdermal, Patch, Patch, extended release, Patch, extended release - Transdermal, For suspension, extended release - Oral, For suspension, extended release, Epidural, Injection, solution - Epidural, Kit, Kit - Oral, Suspension, extended release - Oral, Suspension, extended release

diabetic diarrhea

, 0.1 mg, 0.2 mg, 0.3 mg, 0.5 mg/mL, 0.1 mg/mL, 0.01 mg/hour, 0.02 mg/hour, 0.03 mg/hour, 0.09 mg/mL, 0.17 mg, 0.26 mg, 0.025 mg, 0.15 mg, 25.0 mg

, Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Transdermal, Patch - Transdermal, Patch, Patch, extended release, Patch, extended release - Transdermal, For suspension, extended release - Oral, For suspension, extended release, Epidural, Injection, solution - Epidural, Kit, Kit - Oral, Suspension, extended release - Oral, Suspension, extended release

Hot flashes

, 0.1 mg, 0.2 mg, 0.3 mg, 0.5 mg/mL, 0.1 mg/mL, 0.01 mg/hour, 0.02 mg/hour, 0.03 mg/hour, 0.09 mg/mL, 0.17 mg, 0.26 mg, 0.025 mg, 0.15 mg, 25.0 mg

, Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Transdermal, Patch - Transdermal, Patch, Patch, extended release, Patch, extended release - Transdermal, For suspension, extended release - Oral, For suspension, extended release, Epidural, Injection, solution - Epidural, Kit, Kit - Oral, Suspension, extended release - Oral, Suspension, extended release

Neuralgia, Postherpetic

, 0.1 mg, 0.2 mg, 0.3 mg, 0.5 mg/mL, 0.1 mg/mL, 0.01 mg/hour, 0.02 mg/hour, 0.03 mg/hour, 0.09 mg/mL, 0.17 mg, 0.26 mg, 0.025 mg, 0.15 mg, 25.0 mg

, Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Transdermal, Patch - Transdermal, Patch, Patch, extended release, Patch, extended release - Transdermal, For suspension, extended release - Oral, For suspension, extended release, Epidural, Injection, solution - Epidural, Kit, Kit - Oral, Suspension, extended release - Oral, Suspension, extended release

Human Growth Hormone Deficiency

, 0.1 mg, 0.2 mg, 0.3 mg, 0.5 mg/mL, 0.1 mg/mL, 0.01 mg/hour, 0.02 mg/hour, 0.03 mg/hour, 0.09 mg/mL, 0.17 mg, 0.26 mg, 0.025 mg, 0.15 mg, 25.0 mg

, Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Transdermal, Patch - Transdermal, Patch, Patch, extended release, Patch, extended release - Transdermal, For suspension, extended release - Oral, For suspension, extended release, Epidural, Injection, solution - Epidural, Kit, Kit - Oral, Suspension, extended release - Oral, Suspension, extended release

Attention Deficit Hyperactivity Disorder

, 0.1 mg, 0.2 mg, 0.3 mg, 0.5 mg/mL, 0.1 mg/mL, 0.01 mg/hour, 0.02 mg/hour, 0.03 mg/hour, 0.09 mg/mL, 0.17 mg, 0.26 mg, 0.025 mg, 0.15 mg, 25.0 mg

, Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Transdermal, Patch - Transdermal, Patch, Patch, extended release, Patch, extended release - Transdermal, For suspension, extended release - Oral, For suspension, extended release, Epidural, Injection, solution - Epidural, Kit, Kit - Oral, Suspension, extended release - Oral, Suspension, extended release

Smoking Cessation

, 0.1 mg, 0.2 mg, 0.3 mg, 0.5 mg/mL, 0.1 mg/mL, 0.01 mg/hour, 0.02 mg/hour, 0.03 mg/hour, 0.09 mg/mL, 0.17 mg, 0.26 mg, 0.025 mg, 0.15 mg, 25.0 mg

, Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Transdermal, Patch - Transdermal, Patch, Patch, extended release, Patch, extended release - Transdermal, For suspension, extended release - Oral, For suspension, extended release, Epidural, Injection, solution - Epidural, Kit, Kit - Oral, Suspension, extended release - Oral, Suspension, extended release

Hot Flashes

, 0.1 mg, 0.2 mg, 0.3 mg, 0.5 mg/mL, 0.1 mg/mL, 0.01 mg/hour, 0.02 mg/hour, 0.03 mg/hour, 0.09 mg/mL, 0.17 mg, 0.26 mg, 0.025 mg, 0.15 mg, 25.0 mg

, Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Transdermal, Patch - Transdermal, Patch, Patch, extended release, Patch, extended release - Transdermal, For suspension, extended release - Oral, For suspension, extended release, Epidural, Injection, solution - Epidural, Kit, Kit - Oral, Suspension, extended release - Oral, Suspension, extended release

Warnings

Kapvay has five contraindications. It should not be consumed when experiencing any of the conditions enumerated in the following table.

Kapvay Contraindications

Condition

Risk Level

Notes

Pulse Frequency

Do Not Combine

administration above the C4 dermatome

Do Not Combine

Communicable Diseases

Do Not Combine

bleeding diathesis

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Clonidine may interact with Pulse Frequency

There are 20 known major drug interactions with Kapvay.

Common Kapvay Drug Interactions

Drug Name

Risk Level

Description

1,2-Benzodiazepine

Major

The risk or severity of sedation can be increased when Clonidine is combined with 1,2-Benzodiazepine.

2,5-Dimethoxy-4-ethylthioamphetamine

Major

The risk or severity of sedation can be increased when Clonidine is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.

4-Bromo-2,5-dimethoxyamphetamine

Major

The risk or severity of sedation can be increased when Clonidine is combined with 4-Bromo-2,5-dimethoxyamphetamine.

4-Methoxyamphetamine

Major

The risk or severity of sedation can be increased when Clonidine is combined with 4-Methoxyamphetamine.

5-methoxy-N,N-dimethyltryptamine

Major

The risk or severity of sedation can be increased when Clonidine is combined with 5-methoxy-N,N-dimethyltryptamine.

Kapvay Toxicity & Overdose Risk

The lowest toxic dose of the drug in rats is 126mg/kg. For humans, the lowest toxic dose is 70µg/kg in children, 126µg/kg in women, and 69µg/kg in men. Symptoms of overdose include high or low blood pressure, slow heartbeat, shallow breathing, hypothermia, drowsiness, decreased reflexes, weakness, irritability, and pupil constriction. In severe cases, patients may experience cardiac problems, difficulty breathing, coma, or seizures. It is not recommended to induce vomiting, but gastric lavage or activated charcoal may be helpful if the

image of a doctor in a lab doing drug, clinical research

Kapvay Novel Uses: Which Conditions Have a Clinical Trial Featuring Kapvay?

231 active trials are being conducted to investigate the potential of Kapvay in aiding Smoking Cessation, managing Menopause symptoms and alleviating severe Cancer pain.

Condition

Clinical Trials

Trial Phases

Smoking Cessation

104 Actively Recruiting

Early Phase 1, Phase 4, Not Applicable, Phase 3, Phase 2, Phase 1

Attention Deficit Hyperactivity Disorder

63 Actively Recruiting

Not Applicable, Phase 3, Phase 4, Phase 1, Phase 2

clonidine suppression test

0 Actively Recruiting

growth hormone stimulation test

0 Actively Recruiting

diabetic diarrhea

0 Actively Recruiting

Tourette Syndrome

0 Actively Recruiting

Neuralgia, Postherpetic

0 Actively Recruiting

Human Growth Hormone Deficiency

4 Actively Recruiting

Phase 2, Phase 4, Phase 3

Hot Flashes

6 Actively Recruiting

Phase 2, Not Applicable, Phase 3

Cancer Pain

0 Actively Recruiting

Disease

6 Actively Recruiting

Phase 2, Phase 3, Not Applicable, Phase 1

Hypertensive disease

27 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Phase 3

methadone

0 Actively Recruiting

Attention Deficit and Disruptive Behavior Disorders

6 Actively Recruiting

Not Applicable, Phase 1, Phase 2

clozapine

0 Actively Recruiting

Hot flashes

19 Actively Recruiting

Not Applicable, Phase 4, Phase 2, Early Phase 1, Phase 3

Pheochromocytoma

0 Actively Recruiting

Smoke

0 Actively Recruiting

Kapvay Reviews: What are patients saying about Kapvay?

5

Patient Review

11/19/2011

Kapvay for Attention Deficit Disorder with Hyperactivity

This treatment has been great for my daughter. She's four years old and was diagnosed with ADHD, so she takes Kapvay and risperidone twice a day. They both work well and help her stay focused and calm throughout the day. It was hard to get her to take the pills at first, but after a while she was able to do it on her own and even tells me when it is time to take them.

5

Patient Review

1/12/2012

Kapvay for "Change of Life" Signs

This drug has been a game-changer for my five-year-old. She's been sleeping through the night since we started using it six months ago.

3.7

Patient Review

11/14/2012

Kapvay for Attention Deficit Disorder with Hyperactivity

My son is 12 years old. He is Autistic, ODD, ADHD and Bi-polar. This medication was suppose to treat the impulsive rage that he has. It helped at first, but after the second week, it stopped working. My doctor just decided to change drugs due to how intense my son's 'freak out' moments were getting. The drug did work very well at first-- for a full two days we had NO drama!!! That was a welcomed blessing from above!

3

Patient Review

7/17/2012

Kapvay for Attention Deficit Disorder with Hyperactivity

My daughter didn't seem to concentrate or focus any better on this medication, and it was quite expensive to maintain the prescribed dosage. She did have fewer upper respiratory infections, however.

2.3

Patient Review

5/28/2013

Kapvay for Attention Deficit Disorder with Hyperactivity

If your child has accidentally taken a double dose of this medication, it's important to seek professional medical advice right away.

Patient Q&A Section about kapvay

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is Kapvay prescribed for?

"This drug is used to treat ADHD by itself or with other drugs as part of a comprehensive treatment plan that also includes psychological and social therapies, among other treatments."

Answered by AI

Is Kapvay the same as clonidine?

"Both Kapvay and Catapres contain the drug clonidine. The doses of the two drugs are usually similar. However, Kapvay is used to treat ADHD, while Catapres is used to treat high blood pressure. Catapres is available as an immediate-release tablet, while Kapvay is available as an extended-release tablet."

Answered by AI

How does Kapvay work for ADHD?

"The drug Kapvay works by targeting alpha-2 receptors in the brain in order to potentially reduce symptoms of hyperactivity by altering the way the brain processes emotions, attention, and behavior. While the method by which this drug treats ADHD is not known for certain, the FDA approved its use for pediatric patients aged 6-17 in September of 2010."

Answered by AI

Is Kapvay a stimulant?

"Kapvay is a prescription medicine that is used to treat attention deficit hyperactivity disorder (ADHD). It is supplied as an extended-release tablet. Your doctor may prescribe Kapvay alone or together with other ADHD medicines. Kapvay is not a central nervous system (CNS) stimulant."

Answered by AI

Clinical Trials for Kapvay

Image of UCSF Medical Center at Parnassus in San Francisco, United States.

Blood Pressure Monitoring for Atrial Fibrillation

18+
All Sexes
San Francisco, CA

The goal of this clinical trial is to learn if screening for atrial fibrillation (AFib), a common irregular heart rhythm, through daily home blood pressure monitoring will decrease the time to atrial fibrillation diagnosis in older adults with hypertension. The main question it aims to answer is: \-- Does introducing screening for AFib using a blood pressure monitor with AFib detection technology decrease time to AFib diagnosis in patients with high blood pressure, compared to usual care using a conventional home blood pressure monitor with no AFib detection? Participants will participate in two phases of the study: (1) clinical trial and (2) the registry. During the 6-month clinical trial period, participants will be asked to: * Take blood pressure measurements twice daily * Answer short weekly mobile app-based surveys * If assigned, complete continuous heart monitoring for 2 weeks and complete 1 blood test During the 12-month registry period, participants will be asked to: * Take blood pressure measurements twice daily * Answer monthly mobile app-based surveys Researchers will compare standard blood pressure measurements and AFib screening blood pressure measurements to see if there is a difference in the time to AFib diagnosis and other cardiovascular events. Participants will participate in two phases of the study: (1) trial and (2) the registry. During the 6-month trial period, participants will be asked to: * Take daily blood pressure measurements * Answer short weekly mobile app-based surveys * If assigned, complete continuous heart monitoring for 2 weeks and complete 1 blood test During the 12-month registry period, participants will be asked to: * Take daily blood pressure measurements * Answer monthly mobile app-based surveys

Waitlist Available
Has No Placebo

UCSF Medical Center at Parnassus

Gregory M Marcus, MD, MAS

Omron Healthcare Co., Ltd.

Image of Hāmākua-Kohala Health Center in Honokaa, United States.

Produce Prescription for High Blood Pressure

18+
All Sexes
Honokaa, HI

This multi-site randomized controlled trial uses a community-based approach to evaluate a Food as Medicine program for Native Hawaiian and Pacific Islander (NHPI) adults in Hawaii who have high blood pressure and difficulty affording healthy food. The study has two main goals: (1) to implement a produce prescription program and see if adding personal support from Community Health Workers (CHW) improves blood pressure among other health outcomes, and (2) to determine the program's cost-effectiveness. The study will take place across three Federally Qualified Health Centers in Hawaii. Produce prescription program participants at each site will receive $100 per month, either in the form of produce boxes or monthly vouchers to purchase fruits and vegetables, for 12 months (totaling $1200). In past studies, personal challenges (e.g., lack of transportation, lack of cooking skills) have made it difficult for participants to use the vouchers and/or the purchased produce. In other food as medicine interventions, participants have similarly faced various personal, social, and environmental barriers that limit the program's efficacy. To help participants navigate through these challenges, the investigators want to test adding 1-on-1 support from a CHW throughout the program. Other studies have found that health interventions delivered by CHWs have been effective in reducing blood pressure, blood glucose and weight, especially among vulnerable populations, such as NHPIs and those with food insecurity. The CHWs in this study will receive a training using a curriculum tailored specifically to their community and that is in alignment with the Pilinahā: The Four Connections Framework, which focuses on key connections that Indigenous people seek to attain health and can be employed to overcome health disparities. To test the effectiveness of the added CHW support, there will be two groups of participants: Group 1 (Intervention) will receive the monthly produce prescription ($100 vouchers or produce box) plus meet with a CHW every two months for support with program challenges. Group 2 (Control) will receive the same monthly produce prescription, but will not have meetings with a CHW. The investigators want to see if the added support from CHWs leads to better blood pressure results, among other health outcomes. Upon providing informed consent and enrolling into the program, produce prescription program participants will: * Attend 5 study visits over the one year program. These happen at the start, and then at 3, 6, 9, and 12 months. * Complete health checks at the first visit. This includes getting a home blood pressure monitor and learning about heart health and nutrition. Staff will measure height, weight, waist size, and blood pressure. * Answer surveys about their demographic background, health habits, diet, and culture. * Receive $100 in vouchers every month for 12 months to redeem for fruits and vegetables at a local retailer. * Group 1 will additionally meet with a CHW every two months for 1-on-1 support with any challenges related to the program. * Group 2 will receive monthly reminders to use their vouchers but no CHW meetings. After the program ends, researchers will analyze the financial value of the intervention. This involves calculating the total cost to run the program (including vouchers, CHW training and salaries, and administrative costs) and comparing it to potential savings in healthcare costs. By looking at improvements in blood pressure, researchers can estimate how many heart-related health problems were prevented and how much money was saved on medical care.

Waitlist Available
Has No Placebo

Hāmākua-Kohala Health Center (+2 Sites)

Have you considered Kapvay clinical trials?

We made a collection of clinical trials featuring Kapvay, we think they might fit your search criteria.
Go to Trials
Image of Providence VA Medical Center, Providence, RI in Providence, United States.

Intermittent Theta-Burst Stimulation for ADHD

18 - 65
All Sexes
Providence, RI

Impaired inhibitory response manifests clinically as increased impulsivity, which leads to poorer affective, cognitive, social, and occupational functioning. Neuropsychiatric disorders prevalent among Veterans, such as Attention Deficit/Hyperactivity Disorder (ADHD), are associated with poor inhibitory control. The mainstay of clinical treatment for ADHD is psychostimulants, yet these medications have significant risks, including dependence and numerous side effects. Thus, novel and non-pharmacological therapeutic strategies are needed. Intermittent Theta Burst Stimulation, a newer form of transcranial magnetic stimulation, has emerged as a promising tool for modulating inhibitory neuronal circuits. This research proposal will investigate the feasibility and acceptability of iTBS on inhibitory control and impulsivity through a randomized controlled trial to inform clinical observations. The long-term goal is to improve impulsivity, social and occupational functioning, and enhance the quality of life for Veterans.

Waitlist Available
New This Month

Providence VA Medical Center, Providence, RI

Camila Souza A Cosmo, PhD

Have you considered Kapvay clinical trials?

We made a collection of clinical trials featuring Kapvay, we think they might fit your search criteria.
Go to Trials
Image of National Association of Pasifika Organizations in Fayetteville, United States.

PILI Pasifika Program for Cardiometabolic Conditions

18+
All Sexes
Fayetteville, AR

In this study, the investigators are conducting a Type 3 hybrid effectiveness-implementation trial to evaluate the implementation of the Community Health Workers (CHW)-delivered PILI Pasifika Program (PPP) across 3 regions, the U.S. Affiliated Pacific Islands (USAPI), the continental U.S., and Hawai'i, among 400 Native Hawaiian and Pacific Islander (NHPI) participants in two settings, (clinical and non-clinical) over a 3-year period. The PPP is a 3-month lifestyle intervention that includes a Social Determinants of Health (SDOH) component and was NHPI-adapted from the Diabetes Prevention Program's Lifestyle Program, renamed to the PILI Lifestyle Program (PLP), which demonstrated effectiveness in improving weight, blood pressure, physical activity, and diet among NHPIs. The PPP consists of 8 lifestyle lessons and 4 SDOH activities delivered over a 3-month period. The aims of this study are threefold: 1. To evaluate the implementation of the PPP across multiple community sites using a Type 3 hybrid effectiveness-implementation design guided by established frameworks such as RE-AIM and PRISM. 2. To examine participant-level outcomes associated with PPP implementation, including changes in cardiometabolic risk factors, health behaviors, and SDOH factors from baseline to 3 and 9-month follow-up. 3. To evaluate the cost and cost-effectiveness of implementing the PPP across community settings.

Waitlist Available
Has No Placebo

National Association of Pasifika Organizations (+1 Sites)

Joseph K Kaholokula, PhD

Image of Rush University Medical Center in Chicago, United States.

Food is Medicine for High Blood Pressure

18+
All Sexes
Chicago, IL

The goal of this clinical trial is to assess nutrition incentives and produce vouchers to measure the impacts of food insecurity-related chronic health conditions in adults with hypertension and/or diabetes. The main questions it aims to answer are: * Does participation increase fruit and vegetable consumption for participants? * Does participation reduce individual and household food insecurity? * Does participation reduce healthcare utilization and associated costs? * Does participation lead to improvements in diet-related health outcomes (e.g., hypertension, diabetes)? * Does participation support the local economy by increasing participant spending at local food vendors? Participants will: * Receive 6 months home delivered produce prescription boxes * Receive 6 months match of produce vouchers * Receive nutrition education and participate in Chronic Disease Self-Management classes

Waitlist Available
Has No Placebo

Rush University Medical Center

Traci Simmons, DrPHc, MPH

Have you considered Kapvay clinical trials?

We made a collection of clinical trials featuring Kapvay, we think they might fit your search criteria.
Go to Trials